Promising combo study halted early: hope for advanced blood cancer patients
NCT ID NCT03878199
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This study tested a combination of two drugs, ruxolitinib and CPX-351, in people with advanced myeloproliferative neoplasms (MPN), a type of blood cancer that has progressed. The goal was to find the best dose and see if the combination worked better than CPX-351 alone. Only 12 people took part before the study was stopped early. The results may still help researchers understand how to treat these aggressive cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU
Portland, Oregon, 97239, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Simmons Cancer Center
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.